S-Alpha Therapeutics
S-Alpha Therapeutics is a Seoul-based digital therapeutics company developing evidence-based software medical devices, with lead product SAT-001 (MyoHabit) for pediatric myopia progression and a pipeline across cognitive, oncology, and stress-related indications.
- Company typePrivate
- Founded2019
- HeadquartersSeocho, South Korea
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What S-Alpha Therapeutics does
S-Alpha Therapeutics is a Seoul-based digital therapeutics company founded in 2019 that develops evidence-based software medical devices (SaMD) for unmet medical needs, using data-based software technology that combines bio and digital approaches. The company's lead asset is SAT-001 (MyoHabit), a software-based digital therapeutic designed to delay myopia progression in children aged 5–9; a 48-week confirmatory trial with 111 patients demonstrated a statistically significant reduction in axial length increase with no device-related adverse reactions. S-Alpha operates a broader pipeline of six software product technologies spanning pediatric myopia (SAT-001), mild cognitive impairment (SAT-002), cancer cachexia (SAT-003), pediatric organ function (SAT-006), immunology/infectious disease (SAT-008), and stress disorders (SAT-014).
S-Alpha Therapeutics firmographics
Firmographics- Name
- S-Alpha Therapeutics
- Legal name
- 주식회사 에스알파테라퓨틱스 (S-Alpha Therapeutics, Inc.)
- Website
- https://salphadtx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- S-Alpha Therapeutics is a Seoul-based digital therapeutics company developing evidence-based software medical devices, with lead product SAT-001 (MyoHabit) for pediatric myopia progression and a pipeline across cognitive, oncology, and stress-related indications.
- Ownership category
- akta.pro rank
S-Alpha Therapeutics industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Scientific Research and Development Services (5417), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro industry
- Condition-specific Digital Therapeutics (DTx)Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA)Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)Behavioral Health & Neurocognitive Therapeutics (Digital)Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
Keywords
Where S-Alpha Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Seocho
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
S-Alpha Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Digital Therapeutic Device Sales: Revenue expected from SAT-001 (MyoHabit) digital therapeutic device upon regulatory approval in Korea and other markets, through partnership-driven commercialization model
- Pipeline Product Licensing: Additional revenue streams from other pipeline products (SAT-002, SAT-003, SAT-006, SAT-008, SAT-014) through clinical validation and subsequent commercialization
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
S-Alpha Therapeutics product offering
Product offeringCore offering
S-Alpha Therapeutics develops and commercializes software-based digital therapeutics (SaMD) that deliver evidence-based, non-invasive treatments for unmet medical needs. The lead product SAT-001 (MyoHabit) is a digital therapeutic device for pediatric myopia progression inhibition, supported by confirmatory clinical trial data. The company maintains a broader pipeline covering mild cognitive impairment, cancer cachexia, pediatric organ function, immunology/infectious disease, and stress disorders.
Product overview
S-Alpha Therapeutics is a digital therapeutics (DTx) company developing data-based software technologies that provide evidence-based treatment methods for unmet medical needs. The company operates a multi-product pipeline of software-based medical devices (SaMD). The core product is SAT-001 (MyoHabit), a digital therapeutic for pediatric myopia progression, which has completed confirmatory clinical trials and is planned for regulatory filing. Additional pipeline products include SAT-002 (mild cognitive impairment), SAT-003 (cancer cachexia), SAT-006 (pediatric organ function), SAT-008 (immunology/infectious disease), and SAT-014 (stress disorders).
Differentiator
Problem solved
Functional benefit
Brands
- SAT-001 (MyoHabit): Digital therapeutic device for pediatric myopia progression inhibition.
- SAT-002
- SAT-003
- SAT-006
- SAT-008
- SAT-014
Products and services
- SAT-001 (MyoHabit) Software-based digital therapeutic device designed to delay myopia progression in children aged 5-9 years; evidence-based, non-invasive treatment for pediatric ophthalmology that demonstrated statistically significant delay in axial length increase over 48 weeks with no device-related adverse reactions in a 111-patient confirmatory trial.
- SAT-002 Software product technology designed to inhibit mild cognitive impairment progression, addressing unmet medical needs in cognitive health as part of S-Alpha's multi-indication digital therapeutics pipeline.
- SAT-003 Software product technology aimed at improving cancer cachexia (cancer-related wasting syndrome), part of S-Alpha's digital therapeutics pipeline targeting oncology-related conditions.
- SAT-006 Software product technology designed to improve long-term organ function in pediatric patients, extending S-Alpha's pediatric digital therapeutics focus beyond myopia into broader pediatric care.
- SAT-008 Software product technology related to immunology and infectious diseases, part of S-Alpha's multi-indication digital therapeutics pipeline.
- SAT-014 Software product technology designed to improve stress disorder conditions, part of S-Alpha's multi-indication digital therapeutics pipeline targeting mental health and stress-related conditions.
Quantifiable outcome
- Statistically significant delay in axial length increase in pediatric myopia patients aged 5-9 over 48 weeks
Companies that use S-Alpha Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
S-Alpha Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
S-Alpha Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Rohto PharmaceuticalcoreTechnology transfer and partnership agreement with Japan's Rohto Pharmaceutical for global commercialization of digital therapeutic products including SAT-001 (MyoHabit)
- JungKookDangcoreTechnology transfer and partnership agreement for global commercialization of digital therapeutic products
- LSK Global Pharma ServicesminorOutsourced clinical trial related business operations and related data confirmation and storage
Scale indicators4 records
Expansion highlights5 records
S-Alpha Therapeutics competitors and assessment
Company assessmentDirect peers
- Eyerising International (formerly SightGlass Vision): Eyerising develops Diffusion Optics Technology for slowing pediatric myopia progression, making it the closest direct competitor to S-Alpha's SAT-001 (MyoHabit) on indication, patient population (children), and mechanism category (non-pharmaceutical, device-based myopia management).
- Dopavision: Dopavision is developing a digital therapeutic (MyopiaX) that uses controlled light stimuli delivered via a smartphone app to slow pediatric myopia progression — directly overlapping with S-Alpha's lead indication and DTx delivery model.
- Akili Interactive: Akili pioneered FDA-cleared prescription digital therapeutics (EndeavorRx for pediatric ADHD) and is a direct peer in pediatric, prescription-grade DTx — same regulatory pathway and prescriber channel as S-Alpha's SAT-001.
- Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across multiple indications with pharma-style clinical development, sharing S-Alpha's pipeline breadth, regulatory strategy, and partnership-driven commercialization model.
- Big Health: Big Health creates evidence-based digital therapeutics (e.g., Sleepio for insomnia) targeting unmet needs via clinical validation — directly comparable to S-Alpha's evidence-first DTx approach and SaaMD development model.
- Kaia Health: Kaia Health develops digital therapeutics for musculoskeletal and chronic conditions using AI and behavioral science, overlapping with S-Alpha's multi-indication, evidence-based DTx pipeline and self-management software model.
- Voluntis (Aptar Digital Health): Voluntis (now part of Aptar Digital Health) develops prescription digital therapeutics for chronic conditions, providing direct comparability with S-Alpha on SaMD regulatory pathway, partner-led commercialization, and multi-indication pipeline strategy.
Emerging players
- Cognoa: Cognoa develops AI-driven pediatric diagnostic and therapeutic digital health solutions (e.g., Canvas Dx for autism), aligning with S-Alpha on the pediatric focus and AI/software-as-medical-device regulatory approach.
Broad incumbents
- Otsuka Pharmaceutical: Otsuka received FDA clearance for Rejoyn, a prescription digital therapeutic for depression, establishing a large-pharma precedent for DTx commercialization that mirrors S-Alpha's pharma-partnered (Rohto) go-to-market.
Others
- Rohto Pharmaceutical: Rohto is both a strategic investor ($16.7M round in 2024) and commercialization partner for S-Alpha in Japan; as an established Japanese OTC and ophthalmology player, it is a key ecosystem partner comparable in distribution and category overlap.
Market position
Strengths5 records
Weaknesses3 records
Competitive moat4 records
Key highlights6 records
Customer concentration
S-Alpha Therapeutics social profiles
Digital presenceS-Alpha Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
S-Alpha Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
S-Alpha Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
S-Alpha Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about S-Alpha Therapeutics
What does S-Alpha Therapeutics do?
S-Alpha Therapeutics develops and commercializes software-based digital therapeutics (SaMD) that deliver evidence-based, non-invasive treatments for unmet medical needs. The lead product SAT-001 (MyoHabit) is a digital therapeutic device for pediatric myopia progression inhibition, supported by confirmatory clinical trial data. The company maintains a broader pipeline covering mild cognitive impairment, cancer cachexia, pediatric organ function, immunology/infectious disease, and stress disorders.
Is S-Alpha Therapeutics a public or private company?
S-Alpha Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was S-Alpha Therapeutics founded?
S-Alpha Therapeutics was founded in 2019. It employs 1 to 10 people.
Where is S-Alpha Therapeutics based?
S-Alpha Therapeutics is headquartered in Seocho, South Korea, in the Asia region.
How does S-Alpha Therapeutics make money?
Two revenue lines are on record. Digital Therapeutic Device Sales are the primary driver. The others are pipeline Product Licensing.
Who are S-Alpha Therapeutics's main competitors?
Direct peers on record are Eyerising International (formerly SightGlass Vision), Dopavision, Akili Interactive, Click Therapeutics, Big Health, Kaia Health and Voluntis (Aptar Digital Health). Cognoa is listed as an emerging player. Otsuka Pharmaceutical is listed as a broad incumbent. Rohto Pharmaceutical is listed as an others.
Does S-Alpha Therapeutics have an API?
No public API is recorded for S-Alpha Therapeutics.
What industry is S-Alpha Therapeutics in?
S-Alpha Therapeutics's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAN, DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA). Its NAICS code is 5417 and its SIC code is 3841.